Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/30/2872039/0/en/ASLAN-Pharmaceuticals-to-Host-KOL-Panel-Discussion-on-Treatment-Options-for-Atopic-Dermatitis-Patients-With-an-Inadequate-Response-to-Dupilumab.html
https://www.globenewswire.com/news-release/2024/04/24/2868471/0/en/ASLAN-Pharmaceuticals-Announces-Late-Breaking-Abstract-on-Eblasakimab-in-COPD-Accepted-for-Presentation-at-the-American-Thoracic-Society-International-Conference.html
https://www.globenewswire.com/news-release/2024/04/22/2866887/0/en/ASLAN-Pharmaceuticals-Announces-Positive-Interim-Results-From-Phase-2-Study-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients.html
https://www.globenewswire.com/news-release/2024/04/19/2866393/0/en/ASLAN-Pharmaceuticals-Announces-Receipt-of-Nasdaq-Notice.html
https://www.globenewswire.com/news-release/2024/04/12/2862146/0/en/ASLAN-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/03/27/2853133/0/en/Aslan-Pharmaceuticals-to-Present-at-the-2nd-Annual-H-C-Wainwright-Autoimmune-and-Inflammatory-Disease-Virtual-Conference-Skin-Diseases-Conditions-and-Disorders.html
https://www.globenewswire.com//news-release/2024/03/12/2844956/0/en/ASLAN-Pharmaceuticals-Announces-5-Million-Registered-Direct-Offering.html
https://www.globenewswire.com//news-release/2024/03/11/2843626/0/en/ASLAN-Pharmaceuticals-Provides-TREK-DX-Study-Update-and-Highlights-Potential-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients.html
https://www.globenewswire.com//news-release/2024/03/06/2841265/0/en/ASLAN-Pharmaceuticals-Announces-New-Translational-Data-on-Eblasakimab-in-COPD-and-Appoints-Leading-Respiratory-Experts-as-Scientific-Advisors.html
https://www.globenewswire.com//news-release/2024/01/08/2805232/0/en/ASLAN-Pharmaceuticals-Announces-Receipt-of-Nasdaq-Deficiency-Notice-Regarding-Minimum-Bid-Price-Requirement.html